Navigation Links
Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors
Date:8/29/2014

BOSTON, Aug. 29, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company's Board of Directors.

"Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital," said Remis Bistras, President and CEO of Vittamed. "We are extremely delighted to add his clinical, strategic, and entrepreneurial expertise to our Board."

Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen's University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons.  He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.  

"I am honored to join Vittamed at this exciting time in its history," said Dr. Dagi.  "With the recent CE mark approval for both its products and multiple near-term commercial opportunities, I look forward to helping Vittamed achieve its mission of delivering non-invasive neuromonitoring and diagnostics to patients with unmet medical needs."

He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen's University Belfast for contributions to medicine and public service. 

About Vittamed
Vittamed is a Boston-based company with R&D operations in Lithuania. Using ultrasound based technology, it has developed a suite of clinically proven and validated devices.  The Vittamed 205 is a non-invasive Intracranial Pressure (ICP) meter and the Vittamed 505 is a non-invasive Cerebrovascular Perfusion and Autoregulation monitoring device.  Multiple prospective clinical trials with several hundred patients have proven that the Vittamed devices deliver reliable, clinically acceptable, accurate and precise results as compared to today's standard of care using invasive intraventricular and lumbar puncture ICP measurements.  Recently Vittamed received CE mark for its both devices and is preparing for commercialization in the EU as well as 510 (k) filing in the US.

For more information, please visit www.vittamed.com


'/>"/>
SOURCE Vittamed Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
2. Meditope Biosciences Appoints Prominent Scientific Advisory Board
3. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
4. Sanomedics Signs Definitive Agreement for Acquisition of a prominent Texas based Sleep Services company.
5. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
6. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
7. La Jolla Neurosurgeon Introduces Cutting-Edge Surgery for Scoliosis Patients
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures
10. Vivex Biomedical and Akron Biotech: Collaborative Venture in Regenerative Medicine
11. Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
(Date:12/6/2016)... -- The pen needles market is projected to reach ... in 2016, growing at a CAGR of 11.2% during ... the years, the pen needles market has witnessed various ... demand for safety injections in the healthcare industry. These ... needles with an aim to reduce pain, increase comfort, ...
(Date:12/6/2016)... -- BTL Aesthetics today announced the release of a ... device was effectively redesigned for more efficient, predictable ... The result: Significantly better outcomes in abdominal fat ... versus BTL Vanquish. "We are committed ... with the most highly-advanced devices on the market," ...
Breaking Medicine Technology:
(Date:12/7/2016)... Caloifornia (PRWEB) , ... December 07, 2016 , ... ... present the fifth annual Business Architecture Innovation Summit in Reston, VA on March ... world who will share a range of experiences from a cross-section of industries ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... ... December 06, 2016 , ... According to a November 1 ... consuming too many mints or not drinking enough water, which can cause bad breath ... Care notes that good oral hygiene not only helps reduce the possibility of bad ...
(Date:12/6/2016)... , ... December 06, 2016 , ... Mount Sinai Health ... the Department of Neurosurgery, where clinicians can confer and order 3D models for their ... low-cost fee-for-service basis with quick turnaround times. This resource will be the first ...
(Date:12/6/2016)... , ... December 06, 2016 , ... CarriersEdge, providers of ... a new suite of Driver Wellness courses. Offered in three modules, the courses can ... point so fleets can educate drivers about how to stay healthy on the road. ...
Breaking Medicine News(10 mins):